P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Paul G. Richardson,Sarah A. Holstein,Robert L. Schlossman,Kenneth C. Anderson,Michel Attal,Philip L. McCarthy +5 more
TL;DR: This review article summarizes the efficacy and safety data of lenalidomide maintenance, as monotherapy and in combination with other agents, following ASCT in patients with NDMM and discusses emerging therapies with newer agents in this setting.
Journal ArticleDOI
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.
Nicholas Mitsiades,Nicholas Mitsiades,Ciaran J. McMullan,Vassiliki Poulaki,Joseph Negri,Noopur Raje,Shaji Kumar,Despoina Sikoutri,Teru Hideshima,Dharminder Chauhan,Paul G. Richardson,Robert L. Schlossman,Andrew L. Kung,Heidi Lane,Nikhil C. Munshi,Kenneth C. Anderson,Constantine S. Mitsiades +16 more
TL;DR: The in vitro and in vivo profiles of anti-tumor activity of the selective mTOR inhibitor RAD001 support the notion that RAD001 confers a constellation of pro-apoptotic/anti-proliferative molecular sequelae distinct from those of currently available anti-MM drugs, and suggest that RAD002 may have anti-TumorActivity even against subgroups of MM which may be resistant to other novel therapies which that are currently in clinical development.
Journal ArticleDOI
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius
Saad Z. Usmani,Hareth Nahi,Brendan M. Weiss,Nizar J. Bahlis,Andrew Belch,Henk M. Lokhorst,Peter M. Voorhees,Paul G. Richardson,Clarissa M. Uhlar,Jianping Wang,Ming Qi,Sagar Lonial +11 more
TL;DR: The final safety and efficacy findings for these patients after median follow-up of approximately 3 years are presented and the most common treatment-emergent adverse events observed across the 2 studies were unchanged from previous reports.
Journal ArticleDOI
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Sagar Lonial,Rakesh Popat,Cyrille Hulin,Sundar Jagannath,Albert Oriol,Paul G. Richardson,Thierry Facon,Katja Weisel,Jeremy T. Larsen,Monique C. Minnema,Al-Ola Abdallah,Ashraf Badros,Stefan Knop,Edward A. Stadtmauer,Michael Amatangelo,Min Chen,Tuong Vi Nguyen,Alpesh Amin,Teresa Peluso,N. W. C. J. van de Donk +19 more
TL;DR: Evaluating the safety and clinical activity of iberdomide plus dexamethasone in patients with heavily pretreated relapsed or refractory multiple myeloma showed meaningful clinical activity, and the recommended phase 2 dose was selected.
Journal ArticleDOI
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.
Irene M. Ghobrial,Ravi Vij,Nikhil C. Munshi,Robert L. Schlossman,Jacob P. Laubach,Erica L. Campagnaro,Renee Leduc,Meghan Rourke,Stacey Chuma,Janet Kunsman,Akari M. Dollard,Diane Warren,Brianna Harris,Amy Sam,Kenneth C. Anderson,Paul G. Richardson +15 more
TL;DR: The combination of weekly bortezomib and CCI-779 showed an exciting response rate in patients with relapsed or refractory multiple myeloma, with at least MR or better seen in 79% of patients to date.